This trial is conducted in Europe. The aim of this trial is to evaluate the change in disease activity following 12 weekly s.c. (under the skin) doses of NNC109-0012 compared to placebo in subjects with active Rheumatoid Arthritis (RA).
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01282255?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
